Company: RPID
Filing Date: 2025-04-08
Form Type: DEF 14A
Source: 0001380106-25-000089
Chunk: 25

Company: RAPID MICRO BIOSYSTEMS, INC.
Filing Date: 2025-04-08
Form: DEF 14A
Chunk 25
---
 election as a Class I Director at the Annual Meeting, but does not currently serve on our Board. The principal occupations and business experience, for at least the past five years, of Inese Lowenstein and Dafni Bika, as of April 8, 2025, is set forth above under “Nominees for Class I Directors” on page 10 of this proxy statement. CLASS II DIRECTORS (TERMS TO EXPIRE AT THE 2026 ANNUAL MEETING) The current members of the Board who are Class II Directors are as follows:

| Name              |     |    Served as a 
 Director Since |     |    |     | Positions with Rapid Micro Biosystems |
| Jeffrey Schwartz  |     |           2018 |     |    |     | Director                              |
| Richard Kollender |     |           2009 |     | -1 |     | Director                              |
| Natale Ricciardi  |     |           2016 |     |    |     | Director                              |

_____________________ (1) Mr. Kollender has served as a director since 2009, except for the period from February 2017 to October 2018. 15

TABLE OF CONTENTS The principal occupations and business experience, for at least the past five years, of each Class II Director, as of April 8, 2025, are as follows:

| JEFFREY SCHWARTZ |     | Age 46 |

Jeffrey Schwartz has served as a member of our Board since April 2018 and Chair of our Board from April 2018 to July 2023. Mr. Schwartz currently serves as the Chief Operating Officer of Bain Capital Private Equity, LP,the global private equity operations of Bain Capital, LP. From September 2016 through December 2024, Mr. Schwartz served as a Partner of Bain Capital Life Sciences, LP, where he was a founding member. Prior to co-founding Bain Capital Life Sciences, he was a leader within the healthcare vertical of Bain Capital Private Equity, LP. Mr. Schwartz has served as a Director of Kestra Medical Technologies, Ltd. (Nasdaq:KMTS) since December 2023, and currently serves as the Chair of its board and nomination and governance committee and is a member of the compensation committee. Mr. Schwartz also currently serves on the board of directors of QuVa Pharma, Inc., a privately-held company that provides hospitals with essential medications in ready-to